Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio

Eli Muchtar; Angela Dispenzieri; Nelson Leung; Martha Q. Lacy; Francis K. Buadi; David Dingli; Suzanne R. Hayman; Prashant Kapoor; Yi Lisa Hwa; Amie Fonder; Miriam Hobbs; Wilson Gonsalves; Taxiarchis V. Kourelis; Rahma Warsame; Stephen J. Russell; John A. Lust; Yi Lin; Ronald S. Go; Steven R. Zeldenrust; Robert A. Kyle; S. Vincent Rajkumar; Shaji K. Kumar; Morie A. Gertz

doi:10.1038/s41375-018-0258-y

Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio

Eli Muchtar, Angela Dispenzieri, Nelson Leung, Martha Q. Lacy, Francis K. Buadi, David Dingli, Suzanne R. Hayman, Prashant Kapoor, Yi Lisa Hwa, Amie Fonder, Miriam Hobbs, Wilson Gonsalves, Taxiarchis V. Kourelis, Rahma Warsame, Stephen J. Russell, John A. Lust, Yi Lin, Ronald S. Go, Steven R. Zeldenrust, Robert A. KyleS. Vincent Rajkumar, Shaji K. Kumar, Morie A. Gertz

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Original language	English (US)
Pages (from-to)	527-531
Number of pages	5
Journal	Leukemia
Volume	33
Issue number	2
DOIs	https://doi.org/10.1038/s41375-018-0258-y
State	Published - Feb 1 2019

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-018-0258-y

Cite this

Muchtar, E., Dispenzieri, A., Leung, N., Lacy, M. Q., Buadi, F. K., Dingli, D., Hayman, S. R., Kapoor, P., Hwa, Y. L., Fonder, A., Hobbs, M., Gonsalves, W., Kourelis, T. V., Warsame, R., Russell, S. J., Lust, J. A., Lin, Y., Go, R. S., Zeldenrust, S. R., ... Gertz, M. A. (2019). Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia, 33(2), 527-531. https://doi.org/10.1038/s41375-018-0258-y

Muchtar, E, Dispenzieri, A, Leung, N, Lacy, MQ, Buadi, FK, Dingli, D, Hayman, SR, Kapoor, P, Hwa, YL, Fonder, A, Hobbs, M, Gonsalves, W , Kourelis, TV, Warsame, R, Russell, SJ, Lust, JA, Lin, Y, Go, RS, Zeldenrust, SR, Kyle, RA, Rajkumar, SV , Kumar, SK & Gertz, MA 2019, 'Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio', Leukemia, vol. 33, no. 2, pp. 527-531. https://doi.org/10.1038/s41375-018-0258-y

@article{fca617e5049e42ca9464b58100caac3c,

title = "Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio",

author = "Eli Muchtar and Angela Dispenzieri and Nelson Leung and Lacy, {Martha Q.} and Buadi, {Francis K.} and David Dingli and Hayman, {Suzanne R.} and Prashant Kapoor and Hwa, {Yi Lisa} and Amie Fonder and Miriam Hobbs and Wilson Gonsalves and Kourelis, {Taxiarchis V.} and Rahma Warsame and Russell, {Stephen J.} and Lust, {John A.} and Yi Lin and Go, {Ronald S.} and Zeldenrust, {Steven R.} and Kyle, {Robert A.} and Rajkumar, {S. Vincent} and Kumar, {Shaji K.} and Gertz, {Morie A.}",

note = "Funding Information: Conflict of interest AD: Research funding (Celgene, Millennium, Pfizer, and Janssen), Travel grant (Pfizer); MQL: Research funding (Celgene); DD: Research funding (Karyopharm Therapeutics, Amgen, and Millenium Pharmaceuticals); PK: Research funding (Takeda, Celgene, and Amgen); SK: Consultancy (Celgene, Millennium, Onyx, Janssen, and BMS); and research funding (Celgene, Millennium, Novartis, Onyx AbbVie, Janssen, and BMS). MAG: Consultancy (Milleniu) and honoraria (Celgene, Millenium, Onyx, Novartis, Smith Kline, Prothena, Ionis). The remaining authors declare that they have no conflict of interest. Funding Information: Acknowledgements The study was supported in part by the Jabbs Foundation (Birmingham, United Kingdom), the Henry J. Predolin Foundation (USA), and National Institutes of Health National Cancer Institute grant P50 CA186781.",

year = "2019",

month = feb,

day = "1",

doi = "10.1038/s41375-018-0258-y",

language = "English (US)",

volume = "33",

pages = "527--531",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy

T2 - failure of the serum free light chain ratio

AU - Muchtar, Eli

AU - Dispenzieri, Angela

AU - Leung, Nelson

AU - Lacy, Martha Q.

AU - Buadi, Francis K.

AU - Dingli, David

AU - Hayman, Suzanne R.

AU - Kapoor, Prashant

AU - Hwa, Yi Lisa

AU - Fonder, Amie

AU - Hobbs, Miriam

AU - Gonsalves, Wilson

AU - Kourelis, Taxiarchis V.

AU - Warsame, Rahma

AU - Russell, Stephen J.

AU - Lust, John A.

AU - Lin, Yi

AU - Go, Ronald S.

AU - Zeldenrust, Steven R.

AU - Kyle, Robert A.

AU - Rajkumar, S. Vincent

AU - Kumar, Shaji K.

AU - Gertz, Morie A.

N1 - Funding Information: Conflict of interest AD: Research funding (Celgene, Millennium, Pfizer, and Janssen), Travel grant (Pfizer); MQL: Research funding (Celgene); DD: Research funding (Karyopharm Therapeutics, Amgen, and Millenium Pharmaceuticals); PK: Research funding (Takeda, Celgene, and Amgen); SK: Consultancy (Celgene, Millennium, Onyx, Janssen, and BMS); and research funding (Celgene, Millennium, Novartis, Onyx AbbVie, Janssen, and BMS). MAG: Consultancy (Milleniu) and honoraria (Celgene, Millenium, Onyx, Novartis, Smith Kline, Prothena, Ionis). The remaining authors declare that they have no conflict of interest. Funding Information: Acknowledgements The study was supported in part by the Jabbs Foundation (Birmingham, United Kingdom), the Henry J. Predolin Foundation (USA), and National Institutes of Health National Cancer Institute grant P50 CA186781.

PY - 2019/2/1

Y1 - 2019/2/1

UR - http://www.scopus.com/inward/record.url?scp=85053850911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053850911&partnerID=8YFLogxK

U2 - 10.1038/s41375-018-0258-y

DO - 10.1038/s41375-018-0258-y

M3 - Article

C2 - 30258095

AN - SCOPUS:85053850911

VL - 33

SP - 527

EP - 531

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -

Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this